Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jncics/pky021 http://scihub22266oqcxt.onion/10.1093/jncics/pky021 C6054022!6054022 !30057972     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=30057972 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       JNCI+Cancer+Spectr 2018 ; 2 (3 ): pky021 Nephropedia Template TP {{tp|p=30057972 |t=2018. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management |pdf=|usr=}}{{30057972 }} gab.com Text The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management JO: JNCI Cancer Spectr http://www.kidney.de/pget.php?&tw=1&pmid=30057972 #FOAvip Clinical trials in the past decade have established the antitumor effects of immune checkpoint inhibition as a revolutionary treatment for cancer. Namely, blocking antibodies to cytotoxic T-lymphocyte antigen 4 and programmed death 1 or its ligand have reached routine clinical use. Manipulation of the immune system is not without side effects, and autoimmune toxicities often known as immune-related adverse events (IRAEs) are observed. Endocrine IRAEs, such as hypophysitis, thyroid dysfunction, and insulin-dependent diabetes mellitus, can present with unique profiles that are not seen with the use of traditional chemotherapeutics. In this Review, we discuss the current hypotheses regarding the mechanism of these endocrinopathies and their clinical presentations. Further, we suggest guidelines and algorithms for patient management and future clinical trials to optimize the detection and treatment of immune checkpoint-related endocrinopathies. Twit Text FOAVip The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management ????JNCI Cancer Spectr http://www.kidney.de/pget.php?&tw=1&pmid=30057972 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30057972 #FOAvip English Wikipedia <ref>{{Cite pmid|30057972 }}</ref> The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management #MMPMID30057972 Girotra M ; Hansen A ; Farooki A ; Byun DJ ; Min L ; Creelan BC ; Callahan MK ; Atkins MB ; Sharon E ; Antonia SJ ; West P ; Gravell AE JNCI Cancer Spectr 2018[Jul]; 2 (3 ): pky021 PMID30057972 show ga Clinical trials in the past decade have established the antitumor effects of immune checkpoint inhibition as a revolutionary treatment for cancer. Namely, blocking antibodies to cytotoxic T-lymphocyte antigen 4 and programmed death 1 or its ligand have reached routine clinical use. Manipulation of the immune system is not without side effects, and autoimmune toxicities often known as immune-related adverse events (IRAEs) are observed. Endocrine IRAEs, such as hypophysitis, thyroid dysfunction, and insulin-dependent diabetes mellitus, can present with unique profiles that are not seen with the use of traditional chemotherapeutics. In this Review, we discuss the current hypotheses regarding the mechanism of these endocrinopathies and their clinical presentations. Further, we suggest guidelines and algorithms for patient management and future clinical trials to optimize the detection and treatment of immune checkpoint-related endocrinopathies. ?The Current Understanding of the Endocrine Effects From Immune Checkpo(epmc).pdf DeepDyve Pubget Overpricing